Do you want to read an article? Please log in or register.
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Migraine and Headache
Related content
RECOMMENDED
Migraine and Headache
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD
doi: 10.1177/0333102419894559.
Migraine and Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Headache.
Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD
doi: 10.1111/head.13929.
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
Migraine and Headache
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study
Neurology.
Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA
doi: 10.1212/
COMMENTED
Migraine and Headache
Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
Cephalalgia.
Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA
doi: 10.1177/0333102418789072.
Migraine and Headache
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study
Cephalalgia
Wang SJ, Roxas AA Jr, Saravia B, Kim BK, Chowdhury D, Riachi N, Tai MS, Tanprawate S, Ngoc TT, Jing ZY, Mikol DD, Pandhi S, Wen S, Mondal S, Tenenbaum N, Hours-Zesiger P
doi: 10.1177/03331024211024160
Migraine and Headache
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Headache.
Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW, Aurora SK
doi: 10.1111/head.13691.
Migraine and Headache
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Headache
Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F
doi: 10.1111/head.14032
RECOMMENDED
Migraine and Headache
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 3
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN
doi: 10.1111/head.13766.